Upgrade to SI Premium - Free Trial

Exagen (XGN) PT Raised to $9 at Roth/MKM

August 4, 2026 12:57 PM

Roth/MKM analyst Max Masucci raised the price target on Exagen (NASDAQ: XGN) to $9.00 (from $8.00) while maintaining a Buy rating.

Categories

Analyst PT Change